Aryeh joined the TAP Advisors Health Care group in April 2016. Prior to joining TAP, Mr. Sand was a senior banker in Mizuho’s Health Care Investment Banking group in New York, where he was an integral part of the coverage team for all of the firm’s major health care clients, including Allergan, Amgen, Biogen, Danaher, Express Scripts, Gilead, and Mallinckrodt.
Mr. Sand has extensive M&A advisory and financing expertise, and played meaningful roles in several important transactions including Actavis’ $70bn acquisition of Allergan, Actavis’ $28bn acquisition of Forest Laboratories, Mallinckrodt’s $690MM divestiture of its Nuclear Imaging Business, BWXT Medical’s JV with Global Medical Solutions, Alora Pharma’s $170 MMM acquisition of Osmotica’s legacy business, CutisPharma’s sale to NovaQuest Capital Management, ROMEG Therapeutics licensing of US rights to Gloperba to Avion Pharmaceuticals, SWK Holdings’ restructuring and sale of its interests in ABT Molecular, and Upsher-Smith Laboratories’ divestiture of its women’s health brands.